Jane Henderson
CIK 1422304 · Chief Financial Officer · last filed 2026-10-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
221 CRESCENT ST., SUITE 102B
WALTHAM, MA 02453
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYCA | Director | — | — | — | $0 | 1 | 2026-10-26 |
| Apogee Therapeutics, Inc. (APGE) Delisted | Chief Financial Officer | 0 | $135.07 | $0 | -$2.38M | 17 | 2026-09-03 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | -$2.31M | 9 | 2025-12-09 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 3 | 2025-08-19 |
| IVERIC bio, Inc. (ISEE) Delisted | Director | 22,088 | $39.95 | $882.4K | $0 | 6 | 2023-05-19 |
| Invivyd, Inc. (ADGI) Delisted | Chief Financial Officer | — | $4.64 | — | $0 | 1 | 2022-02-01 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 4 | 2021-05-10 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | — | — | — | $0 | 2 | 2018-07-11 |
| VYGR | Sr. V.P. & CFO, Corp. Dev. | 0 | $1.72 | $0 | -$1.03M | 4 | 2018-03-26 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-05-23 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Chief Financial Officer & CBO | 125,000 | — | — | $23.5K | 3 | 2008-05-05 |
Recent Filings · Page 6 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-21 | Carisma Therapeutics Inc. (SESN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-16 | IVERIC bio, Inc. (ISEE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-11 | IVERIC bio, Inc. (OPHT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-14 | Carisma Therapeutics Inc. (SESN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-26 | VYGR | Mixed | — | -$276.9K | EDGAR |
| 2018-03-20 | VYGR | Mixed | — | -$175.5K | EDGAR |
| 2018-03-09 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2018-01-17 | IVERIC bio, Inc. (OPHT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-23 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-05 | VYGR | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.